List of Excipients in Branded Drug PRIFTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
sanofi-aventis US LLC	PRIFTIN	rifapentine	0088-2102	ALUMINUM OXIDE
sanofi-aventis US LLC	PRIFTIN	rifapentine	0088-2102	CALCIUM STEARATE
sanofi-aventis US LLC	PRIFTIN	rifapentine	0088-2102	CELLULOSE, MICROCRYSTALLINE
sanofi-aventis US LLC	PRIFTIN	rifapentine	0088-2102	EDETATE DISODIUM
sanofi-aventis US LLC	PRIFTIN	rifapentine	0088-2102	FD&C BLUE NO. 2
sanofi-aventis US LLC	PRIFTIN	rifapentine	0088-2102	FERRIC OXIDE RED
sanofi-aventis US LLC	PRIFTIN	rifapentine	0088-2102	HYDROXYPROPYL CELLULOSE

# PRIFTIN Excipient Strategy and Commercial Opportunities: Rifapentine Formulation, Pediatric Delivery, and Generic Competition

Last updated: August 9, 2026

Priftin is Sanofi’s rifapentine product, approved in the United States as film-coated 150 mg tablets. The strongest excipient opportunities are not in replacing the rifapentine molecule, which is genericized and clinically established, but in improving dissolution, tablet size, pediatric administration, fixed-dose combination compatibility, stability, and adherence for tuberculosis treatment regimens. The most attractive commercial targets are dispersible or mini-tablet formulations, high-throughput generic tablets, co-packaged regimens, and excipient systems that support low-cost manufacturing in tuberculosis-endemic markets.

What is Priftin and which formulations are commercially marketed?

Priftin contains rifapentine, a rifamycin antibacterial used with other drugs for tuberculosis treatment and with isoniazid for once-weekly treatment of latent tuberculosis infection. The U.S. product is a 150 mg film-coated tablet supplied in bottles of 24 tablets and other package configurations depending on market and regulatory presentation.[1]

Product attribute	Priftin profile
Active ingredient	Rifapentine
Strength	150 mg tablet
Dosage form	Film-coated tablet
U.S. sponsor	Sanofi-Aventis U.S. LLC
Main latent-TB regimen	Once weekly rifapentine plus isoniazid for 12 weeks, commonly called 3HP
Active-TB use	Combination therapy with other antitubercular agents
Pediatric use	Latent-TB indication includes children aged 2 years and older; active pulmonary-TB labeling has different age and regimen requirements
Administration	Taken with food under the prescribing information
Key formulation issue	Rifapentine has limited aqueous solubility and requires reliable oral exposure

The commercial product is a conventional solid oral dosage form. Its excipient composition is disclosed in the FDA prescribing information and product labeling, but the exact manufacturing process, grade selection, supplier allocation, and quantitative formula are generally proprietary.[1]

What excipients are used in Priftin tablets?

The Priftin label identifies a conventional tablet excipient system that includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate, hypromellose, talc, titanium dioxide, and colorants.[1]

Functional role of the Priftin excipients

Excipient or excipient class	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Cost-effective tablet mass builder; requires control of moisture and lactose compatibility
Microcrystalline cellulose	Filler and dry-binder	Supports tablet hardness and robust compression
Croscarmellose sodium	Superdisintegrant	Promotes tablet breakup and drug release
Povidone	Binder	Supports granule or tablet cohesion
Sodium lauryl sulfate	Surfactant and wetting agent	Can improve wetting of poorly water-soluble rifapentine
Magnesium stearate	Lubricant	Supports tablet ejection but can impair wetting if over-lubrication occurs
Hypromellose	Film-coating polymer	Protects the tablet and supports swallowability and appearance
Talc	Coating aid and anti-tacking agent	Supports film-coating process control
Titanium dioxide and iron-based colorants	Opacifier and color system	Product identification and visual differentiation

The most strategically important components are sodium lauryl sulfate, croscarmellose sodium, povidone, microcrystalline cellulose, and the coating system. These ingredients influence wetting, disintegration, tablet strength, dissolution, and manufacturability.

How does rifapentine’s drug substance affect excipient selection?

Rifapentine is a high-dose, poorly water-soluble rifamycin. The formulation must balance dose loading with adequate disintegration and dissolution. Surfactant selection, particle-size control, granulation conditions, and lubricant level can materially affect performance.

A replacement excipient system should be evaluated for:

1. Dissolution across physiologically relevant pH conditions.
2. Food-state performance because Priftin is administered with food.
3. Chemical and physical stability during storage.
4. Compatibility with rifapentine and other antitubercular agents.
5. Tablet size and swallowability.
6. Content uniformity at commercial scale.
7. Compatibility with pediatric dosage forms.
8. Supply security in low- and middle-income markets.

The key risk is over-optimizing tablet strength at the expense of rifapentine release. Hydrophobic lubrication, excessive binder concentration, or an unsuitable coating can slow wetting and dissolution. A formulation that passes conventional tablet tests but produces variable rifapentine exposure would create regulatory and clinical risk.

What excipient strategies could improve Priftin?

1. Superdisintegrant and wetting optimization

The most direct reformulation opportunity is to improve tablet breakup and rifapentine wetting without changing the active ingredient. Candidate approaches include:

• Combining croscarmellose sodium with sodium starch glycolate or crospovidone.
• Optimizing intragranular and extragranular disintegrant placement.
• Replacing or supplementing sodium lauryl sulfate with a lower-irritancy surfactant.
• Testing poloxamers, sodium docusate, or other wetting agents.
• Reducing magnesium stearate exposure or shortening lubrication time.
• Using finer, controlled rifapentine particle sizes.

Any surfactant replacement would need toxicological, extractables, taste, and global regulatory assessment. Sodium lauryl sulfate is familiar to regulators but can create tolerability and formulation-performance tradeoffs.

2. Direct-compression platforms

A direct-compression formulation could reduce process steps, solvent use, and manufacturing cost. A suitable platform would typically require:

• A directly compressible cellulose or lactose grade.
• A high-efficiency disintegrant.
• Controlled-flow rifapentine particles.
• A lubricant system that preserves dissolution.
• Robust segregation and content-uniformity controls.

Direct compression has particular value for generic manufacturers serving high-volume procurement programs. Its weakness is that rifapentine loading, powder flow, and particle-size variability may limit compression performance.

3. Roller-compacted or dry-granulated tablets

Dry granulation can improve powder flow without introducing water or organic solvent. This approach may be useful where rifapentine stability or moisture sensitivity limits wet granulation. It can also reduce production complexity in facilities with constrained utilities.

The principal development questions are ribbon strength, granule densification, tablet porosity, dissolution, and the effect of milling on rifapentine particle distribution.

4. Film-coating redesign

The film coat is a secondary opportunity with commercial value. A thinner, aqueous, low-weight-gain coating could reduce cost and tablet mass. A taste-masking or swallowing-oriented coating could help pediatric administration, although a conventional swallowed tablet remains difficult for younger children.

Coating changes must preserve:

• Appearance and product identification.
• Stability under heat and humidity.
• Tablet hardness and friability.
• Disintegration time.
• Packaging compatibility.
• Light protection where necessary.

5. Pediatric mini-tablets and dispersible tablets

Pediatric delivery is the clearest unmet formulation opportunity. Children receiving latent-TB treatment may struggle with large 150 mg tablets, particularly when rifapentine is combined with isoniazid and other agents.

Potential dosage forms include:

• 50 mg or 75 mg mini-tablets.
• Multiparticulates in sachets.
• Film-coated granules.
• Dispersible tablets.
• Orodispersible tablets.
• Ready-to-use or reconstituted suspensions.

A pediatric product must address rifapentine’s strong color and potential taste burden. Taste masking could use polymeric coatings, ion-exchange systems, lipid barriers, or flavor-compatible multiparticulates. The formulation must also avoid excipients that create age-related restrictions.

WHO and global tuberculosis programs have emphasized child-friendly formulations for preventive and active-TB treatment. A lower-strength rifapentine product could reduce tablet splitting, dosing errors, and pill burden.[2,3]

What are the strongest commercial opportunities for Priftin excipients?

Which excipient opportunities have the highest commercial value?

Opportunity	Commercial value	Development complexity	Primary buyer
Low-cost generic 150 mg tablet platform	High	Moderate	Generic manufacturers
Pediatric mini-tablet or dispersible product	High	High	Originators, global-health suppliers, public programs
Rifapentine-isoniazid co-packaging	High	Moderate	TB programs and distributors
Fixed-dose combination tablet	Very high	Very high	Global manufacturers and public purchasers
Improved dissolution excipient system	Moderate to high	Moderate	Generic and specialty manufacturers
Taste-masked multiparticulate product	Moderate to high	High	Pediatric and global-health developers
Moisture-robust packaging and coating system	Moderate	Low to moderate	Contract manufacturers
Continuous manufacturing excipient platform	Moderate	High	Large-scale generic producers

The most defensible near-term opportunity is a scalable 150 mg generic tablet with improved dissolution and low manufacturing cost. The highest strategic value is a pediatric or fixed-dose combination product because it can reduce pill burden and create procurement advantages.

Can excipients support a rifapentine-isoniazid fixed-dose combination?

Yes. A fixed-dose combination would create a substantial formulation challenge because rifapentine and isoniazid have different dose, solubility, stability, and compatibility profiles.

Important development issues include:

• Chemical compatibility between rifapentine and isoniazid.
• Rifapentine dissolution at the required dose.
• Protection against moisture-driven degradation.
• Uniformity across a high-dose combination tablet.
• Food-effect consistency.
• Stability in tropical climates.
• Acceptability of tablet size.
• Pediatric dose flexibility.

A bilayer tablet, multilayer tablet, coated granule-in-tablet system, or physically separated multiparticulate approach may be more practical than a simple powder blend. The excipient system could become part of a defensible formulation patent if it demonstrates improved stability, dissolution, bioavailability, or pediatric usability.

What regulatory barriers affect Priftin reformulation?

A new rifapentine dosage form would generally require a regulatory pathway tied to the product’s intended use. A conventional generic tablet may be eligible for an abbreviated pathway if it satisfies applicable bioequivalence and product-quality requirements. A new pediatric dosage form, fixed-dose combination, or modified-release product may require additional clinical, pharmacokinetic, or bridging evidence.

The FDA inactive ingredient database can support selection of previously used excipients, but prior use in an approved product does not automatically establish suitability at a new route, dose, population, or dosage form.[4]

Critical regulatory studies may include:

• Comparative dissolution.
• Biowaiver assessment where permitted.
• Single-dose and fed-state bioequivalence.
• Food-effect evaluation.
• Stability under ICH and tropical-climate conditions.
• Microbiological quality for liquid or reconstituted products.
• Pediatric acceptability and dosing studies.
• Drug-drug interaction assessment for combination products.

Rifapentine’s established use does not eliminate the need to show that an excipient change does not alter exposure or therapeutic performance.

When does Priftin lose exclusivity, and what is the generic-entry risk?

Rifapentine is an established small-molecule drug. The main commercial issue is therefore generic and formulation competition rather than biosimilar competition. Biosimilar risk does not apply because Priftin is not a biologic.

The original compound and product exclusivity associated with an older small-molecule product would not normally protect a modern commercial strategy. Current competitive barriers are more likely to involve:

• Bioequivalence execution.
• Manufacturing scale.
• Rifapentine drug-substance supply.
• Quality-system capability.
• Public-procurement qualification.
• Pediatric formulation know-how.
• Fixed-dose combination development.
• Patent claims directed to specific formulations or uses.

An excipient-based patent would need more than a list of conventional ingredients. Stronger claims would connect the excipient system to a measurable technical result, such as improved rifapentine dissolution, reduced food dependence, enhanced stability, lower tablet burden, or improved pediatric acceptability.

Are there Paragraph IV, Orange Book, or litigation opportunities?

Priftin is an FDA-approved small-molecule product and therefore can be evaluated through the conventional generic framework, including Orange Book listing and potential Paragraph IV certification where applicable. The commercial relevance of any listed patent depends on its current expiration, delisting status, claims, and whether it covers the approved product or only a method of use.

For excipient-driven competitors, the principal legal exposure is likely to arise from:

• Formulation patents.
• Pediatric dosage-form patents.
• Fixed-dose combination patents.
• Manufacturing-process patents.
• Crystalline or particle-size patents.
• Method-of-treatment patents.

A generic tablet with a different excipient composition may avoid a narrow formulation claim but still require analysis of product, process, and method-of-use patents. Regulatory certification strategy should be based on the current FDA Orange Book and patent records rather than the historical patent portfolio associated with rifapentine.[5]

No biosimilar pathway, biosimilar interchangeability issue, or biologic patent dance applies to Priftin.

How does Priftin compare with other rifamycin products?

Product	Active ingredient	Typical formulation position	Excipient opportunity
Priftin	Rifapentine	150 mg film-coated tablet	Pediatric, dissolution, fixed-dose combination, lower-cost generic
Rifadin/Rifampin	Rifampin	Capsules, tablets, oral suspension in some markets	Solubility, stability, liquid and pediatric delivery
Rifabutin products	Rifabutin	Capsules	Lower-volume specialty formulation and supply opportunities

Rifapentine has a distinct commercial position because once-weekly 3HP treatment can reduce administration frequency compared with longer preventive regimens. The formulation opportunity is tied to adherence and public-health delivery, not only to tablet production cost.[2,3]

What manufacturing and supply-chain barriers affect excipient commercialization?

A successful excipient strategy must work in the markets where tuberculosis products are purchased. The formulation should minimize dependence on specialized equipment, imported coating materials, or narrow supplier specifications.

Priority supply-chain controls include:

• Dual sourcing for microcrystalline cellulose, lactose, disintegrant, surfactant, and coating materials.
• Excipient grades with compendial and regional regulatory acceptance.
• Low-moisture packaging suitable for hot and humid climates.
• Consistent rifapentine particle-size distribution.
• Process capability for high-dose tablets.
• Compatibility with high-speed rotary compression.
• Stability data under Zone IV conditions.
• Low-cost pack sizes for public-health procurement.

A formulation that requires a proprietary solubilizer or specialized lipid process may offer stronger intellectual property but reduce adoption in price-sensitive markets. A simpler platform using established compendial excipients may produce lower margins but achieve broader procurement access.

What licensing and partnership models are available?

Potential commercial structures include:

1. Licensing a pediatric rifapentine formulation to a global-health supplier.
2. Supplying a proprietary excipient premix to generic tablet manufacturers.
3. Co-developing a rifapentine-isoniazid fixed-dose combination.
4. Licensing taste-masking technology for pediatric multiparticulates.
5. Contract manufacturing of low-cost tablets or sachets.
6. Providing formulation and regulatory support to regional TB suppliers.
7. Establishing supply agreements for qualified excipient grades.

The strongest licensing asset would combine formulation performance with regulatory data, manufacturing transferability, and procurement economics. An excipient alone is easier to substitute unless it is linked to a protected process, a validated performance advantage, or a reliable supply agreement.

Key Takeaways

• Priftin is a 150 mg rifapentine film-coated tablet used principally in tuberculosis treatment and latent-TB prevention.
• Its current excipient system is conventional and includes lactose, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate, and film-coating components.
• The central formulation challenge is achieving reliable rifapentine dissolution while maintaining high-dose tablet manufacturability.
• Pediatric mini-tablets, dispersible tablets, taste-masked multiparticulates, and lower-strength presentations offer the clearest product opportunities.
• A rifapentine-isoniazid fixed-dose combination has high commercial value but significant compatibility, stability, dose-uniformity, and regulatory challenges.
• Generic competition is more relevant than biosimilar competition.
• Strong formulation IP should claim a demonstrated technical result, not merely a conventional excipient list.
• Public-health procurement, tropical stability, manufacturing simplicity, and excipient supply security will determine commercial adoption.

FAQs

Can sodium lauryl sulfate be replaced in a rifapentine tablet?

Yes. Potential replacements include other surfactants or wetting systems, but the substitute must preserve dissolution, stability, tolerability, and bioequivalence. The change would require comparative pharmaceutical and regulatory evaluation.

Is a rifapentine oral suspension commercially attractive?

Yes, particularly for children, but physical stability, taste, sedimentation, dose uniformity, preservative selection, and storage conditions create substantial development requirements. A dry powder for reconstitution may be more practical than a ready-to-use suspension in some markets.

Could a rifapentine product use amorphous solid dispersion technology?

Potentially. Amorphous dispersion or spray-dried systems could improve apparent solubility, but they may increase manufacturing complexity, moisture sensitivity, and packaging requirements. The technology is more likely to be justified for a differentiated formulation than for the lowest-cost generic tablet.

What excipient is most important for rifapentine dissolution?

No single excipient determines performance. The interaction among wetting agent, disintegrant, particle size, lubricant level, granulation method, and coating is more important than any one ingredient.

Would a rifapentine fixed-dose combination reduce patent risk?

Not necessarily. A fixed-dose combination may avoid some single-product claims but can create new exposure to combination, formulation, manufacturing, and method-of-use patents. The applicable patent position must be assessed claim by claim.

References

1. U.S. Food and Drug Administration. (2024). Priftin (rifapentine) tablets, 150 mg: Prescribing information. Sanofi-Aventis U.S. LLC.
2. Centers for Disease Control and Prevention. (2020). latent tuberculosis infection: A guide for primary health care providers. U.S. Department of Health and Human Services.
3. World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 5, management of tuberculosis in children and adolescents. World Health Organization.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. Center for Drug Evaluation and Research.